Heparin Market Research focuses on the key trends prevailing in the Global Heparin Industry sector. The existing Industry scenario has been studied and future projections with respect to the sector have also been investigated. Market study report comprises evaluation of numerous influential factors including industry overview in terms of historic and present situation, key manufacturers, product/service application and types, key regions and marketplaces, forecast estimation for global market share, revenue and CAGR.
𝐆𝐞𝐭 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐰𝐢𝐭𝐡 𝐋𝐚𝐭𝐞𝐬𝐭 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬 @ https://www.coherentmarketinsights.com/insight/request-sample/2602
Heparin is an anticoagulant (blood thinner) that prevents the formation of blood clots. It is used for the treatment and prevention of blood clots caused by certain medical conditions or medical procedures. Furthermore, heparin is used in blood transfusion, to treat blood clotting disorders, and for prophylaxis treatment. It is also used for the treatment of disseminated intravascular coagulation, a serious blood condition. Heparin can be used alone or in combination.
The global heparin market size was valued at US$ 9.4 billion in 2017 and is expected to witness a CAGR of 5.1% over the forecast period (2018 – 2026).
High prevalence of deep vein thrombosis, pulmonary embolism, and coronary heart disease is expected to boost the growth of the global heparin market over the forecast period. Heparin is extensively used to treat deep vein thrombosis, for dialysis, and in most cardiac surgeries. It is also used to prevent the formation of blood clots during kidney dialysis, open-heart surgery, blood transfusions, and bypass surgery. With the rising prevalence of chronic kidney disease (CKD) across the globe, number of kidney dialysis procedures is also increasing, which in turn is also expected to increase the demand for heparin. For instance, as reported by Kidney Care UK, in 2016, more than 3 million individuals in the United Kingdom suffered from CKD.
Moreover, rising prevalence of coronary heart disease and vein thrombosis and rise in number of surgeries around the world is expected to boost growth of the global heparin market. For instance, as per the American Heart Association, in 2018, one in seven deaths in the United States are due to coronary heart disease, taking an estimated 366,800 lives each year. Moreover, the prevalence for myocardial infarction (MI) in the U.S. is about 7.9 million.
𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞 𝐰𝐢𝐭𝐡 𝐋𝐚𝐭𝐞𝐬𝐭 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬 @ https://www.coherentmarketinsights.com/insight/request-pdf/2602
Side effects of heparin, such as bleeding from pen wounds or surgical sites, mouth and gums, ovaries and uterus, and intestines and stomach, are expected to hamper the growth of the global heparin market. Another side effect of heparin is known as heparin-induced thrombocytopenia (HIT) in which the drug prompts the body’s immune system to develop antibodies against its own platelets, increasing the risk of bleeding due to a decrease in platelets.
By Product Type:
- Unfractionated Heparin (UH)
- Low Molecular Weight Heparin (LMWH)
- Ultra-low Molecular Weight Heparin (ULMW)
By Dosage Form:
- North America
- Latin America
- Asia Pacific
- Middle East
Europe is expected to witness substantial growth in the global heparin market due to the rising prevalence of acute myocardial infarction (AMI) and growing geriatric population. Survivors of AMI are at higher risk of recurrent MI and heart disease, such as stroke. For instance, as per the Lancet journal, in 2017, AMI is one of the leading cause of hospital admission and mortality in the United Kingdom.
Asia Pacific is expected to witness robust growth in the global heparin market due to the high prevalence of MI in the region. For instance, according to the study published in 2015 by the National Center for Biotechnology Information (NCBI), Asian population is more vulnerable to myocardial infarction than white people.
Major players active in the global heparin market are Baxter International Inc., Bristol-Myers Squibb Co., B. Braun Melsungen AG, Dr. Reddy’s Laboratories Ltd., Leap Labchem Co., Teva Pharmaceutical Industries Ltd., Fresenius SE & Co. KGaA, LEO Pharma A/S, Sanofi S.A., Pfizer, Inc., Syntex S.A., United Biotech (P) Ltd., and Anselm Pharmaceuticals, among others.
𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐓𝐡𝐢𝐬 𝐏𝐫𝐞𝐦𝐢𝐮𝐦 𝐑𝐞𝐩𝐨𝐫𝐭 𝐓𝐨 𝐀𝐜𝐜𝐞𝐬𝐬 𝐅𝐮𝐥𝐥 𝐈𝐧𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐨𝐧 (Flat USD 2000 OFF)@ https://www.coherentmarketinsights.com/promo/buynow/2602
𝐀𝐛𝐨𝐮𝐭 𝐂𝐨𝐡𝐞𝐫𝐞𝐧𝐭 𝐌𝐚𝐫𝐤𝐞𝐭 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.